PO:07:103 | Tocilizumab use in patients with rheumatoid arthritis and malignancy: a monocentric experience
Background. In 2024, the EULAR published a set of points to consider for initiating targeted therapy in rheumatoid arthritis (RA) patients with a history of malignancy, indicating TNF inhibitors are preferred in solid tumors, while rituximab is recommended for hematological malignancies. Although t...
I tiakina i:
| Kaituhi matua: | |
|---|---|
| Hōputu: | Artigo |
| Reo: | Inglês |
| I whakaputaina: |
PAGEPress Publications
2025-11-01
|
| Rangatū: | Reumatismo |
| Ngā marau: | |
| Urunga tuihono: | https://www.reumatismo.org/reuma/article/view/2021 |
| Ngā Tūtohu: |
Kāore He Tūtohu, Me noho koe te mea tuatahi ki te tūtohu i tēnei pūkete!
|